STACEY GODMAN, CRNP
Nurse Practitioner · WOBURN, MA
Individual Active NPI 1689902595
Medicare payment data Part B · 2024
| Year | Beneficiaries | Services | Submitted | Allowed | Paid |
|---|---|---|---|---|---|
| 2024 | 402 | 198,123 | $16,878,180 | $5,903,741 | $4,698,813 |
| 2023 | 262 | 123,807 | $13,156,784 | $4,543,752 | $3,614,620 |
| 2022 | 245 | 115,554 | $13,281,346 | $4,479,025 | $3,568,629 |
Top procedures (2024)
| HCPCS | Description | Services | Avg allowed | Avg paid |
|---|---|---|---|---|
| J1306 | Injection, inclisiran, 1 mg | 28,116 | $12 | $9 |
| J2356 | Injection, tezepelumab-ekko, 1 mg | 21,000 | $18 | $14 |
| J3245 | Injection, tildrakizumab, 1 mg | 8,300 | $135 | $108 |
| J3380 | Injection, vedolizumab, intravenous, 1 mg | 6,900 | $22 | $17 |
| J2182 | Injection, mepolizumab, 1 mg | 4,100 | $30 | $24 |
| J3032 | Injection, eptinezumab-jjmr, 1 mg | 3,800 | $18 | $14 |
| J2357 | Injection, omalizumab, 5 mg | 2,955 | $38 | $30 |
| J0517 | Injection, benralizumab, 1 mg | 2,700 | $165 | $131 |
| J1745 | Injection, infliximab, excludes biosimilar, 10 mg | 1,570 | $31 | $25 |
| J0897 | Injection, denosumab, 1 mg | 1,080 | $25 | $20 |
| 96372 | Injection of drug or substance under skin or into muscle | 570 | $12 | $10 |
| J2919 | Injection, methylprednisolone sodium succinate, 5 mg | 504 | $0 | $0 |
Taxonomy & licensure
| Specialty | Code | Primary | License | State |
|---|---|---|---|---|
| Nurse Practitioner | 363L00000X | ✓ | SP010635 | PA |
| Registered Nurse | 163W00000X | RN546954 | PA |
Medicare eligibility
- Part B
- Yes
- DME
- Yes
- Home health
- Yes
- Power mobility
- Yes
- Hospice
- No
Other Nurse Practitioner providers in Massachusetts
- NPI 1558952069
- NPI 1053209718
- NPI 1477523009
- NPI 1811569825
- NPI 1548853096
- NPI 1962110965
- NPI 1104977354
- NPI 1912448622
Source: NPPES (public domain) and CMS Medicare Physician & Other Practitioners data. Not affiliated with CMS, NPPES, or any government agency.